Dexcom G7: The Gold Standard CGM for Glucose Monitoring and Metabolic Health

A landmark study reveals that 40% of people with “normal” fasting glucose would be reclassified as prediabetic under continuous monitoring. The implications for how we measure metabolic health are profound.

A single fasting glucose reading has been the cornerstone of diabetes screening for decades. You fast overnight, get your blood drawn, and if the number comes back below 100 mg/dL, you are told your metabolic health is fine. But a 2024 study published in Nature Medicine by Shilo and colleagues at the Weizmann Institute of Science challenged this assumption in a way the medical community cannot ignore. The researchers placed continuous glucose monitors on 8,315 nondiabetic adults aged 40 to 70 and tracked their fasting glucose across 59,565 morning windows. The mean fasting glucose was 96.2 mg/dL, but the day-to-day standard deviation within the same individual was 7.52 mg/dL. Among 5,328 individuals initially classified as having normal fasting glucose based on their first measurement, 40% would have been reclassified into the prediabetic range and 3% into the diabetic range based on subsequent measurements during the study period.

The implication is striking: a single fasting glucose snapshot misses metabolic dysfunction that is already underway in a significant portion of the population. Continuous glucose monitoring, once reserved exclusively for insulin-dependent diabetics, is emerging as the tool that closes this diagnostic gap. And at the center of this shift sits the Dexcom G7, the most widely used clinical-grade continuous glucose monitor in the world.

What Is the Dexcom G7?

The Dexcom G7 is a continuous glucose monitoring (CGM) system that measures interstitial glucose levels every five minutes through a small sensor worn on the upper arm or abdomen. Each sensor lasts 10 days, after which it is replaced with a new unit. The G7 is the smallest CGM currently available, roughly the diameter of a U.S. quarter, and features a simplified one-piece applicator that combines the sensor and transmitter into a single disposable unit.

The device streams real-time glucose data directly to a compatible smartphone or smartwatch, including the Apple Watch and select Garmin models. Users see their current glucose level, a trend arrow indicating the direction and rate of change, and customizable high and low alerts that notify them when glucose moves outside their target range. The companion app displays an eight-hour glucose trace, daily patterns, and a summary metric called “time in range” that quantifies the percentage of the day spent within a healthy glucose window.

The Dexcom G7 is FDA cleared for use by individuals with type 1 and type 2 diabetes and can be used for insulin dosing decisions without a confirmatory fingerstick. While the device requires a prescription for diabetic use, Dexcom also offers the Stelo, an over-the-counter variant for general wellness monitoring. The G7 represents Dexcom’s seventh generation of continuous glucose technology, building on more than two decades of clinical development and regulatory approvals.

The Science Behind Continuous Glucose Monitoring

Continuous glucose monitoring measures interstitial fluid glucose, a close proxy for blood glucose, at near-continuous frequency. Unlike a single fasting glucose test or even an HbA1c measurement (which reflects a three-month average), CGM captures the full dynamic range of glucose behavior: fasting levels, postprandial spikes after meals, nocturnal dips, the glucose impact of exercise, stress, and sleep quality, and the speed at which glucose returns to baseline after a perturbation.

The clinical value of this granularity extends well beyond diabetes management. The Shilo et al. 2024 study in Nature Medicine demonstrated that fasting glucose in nondiabetic adults is far more variable than previously assumed. With a day-to-day standard deviation of 7.52 mg/dL, an individual with a “true” fasting glucose of 95 mg/dL could easily register 88 mg/dL one morning and 103 mg/dL the next, crossing the prediabetic threshold without any change in actual metabolic status. CGM eliminates this measurement noise by providing hundreds of data points per day instead of a single snapshot.

Glycemic variability, the magnitude and frequency of glucose fluctuations throughout the day, has emerged as an independent risk factor for cardiovascular disease and metabolic dysfunction. Research from the broader medical research community has shown that large postprandial glucose spikes (even in individuals with “normal” average glucose) are associated with increased oxidative stress, endothelial dysfunction, and inflammatory signaling. CGM is the only tool that captures these transient spikes, which are invisible on standard lab work.

A 2024 study published in Nature Communications by Brandhorst and colleagues demonstrated that metabolic interventions, specifically a fasting-mimicking diet protocol, reduced biological age by an average of 2.5 years as measured through blood biomarker panels. The connection to CGM is direct: glucose metabolism is a central driver of biological aging, and CGM provides the real-time feedback necessary to optimize dietary and lifestyle interventions that target metabolic health. When you can see exactly how a meal, a workout, or a night of poor sleep affects your glucose in real time, you can calibrate your behavior with a precision that was previously impossible outside a clinical research setting.

The broader longevity research community increasingly recognizes metabolic dysfunction as one of the Four Villains, the primary chronic disease threats to healthspan. Insulin resistance and glycemic dysregulation are upstream drivers of cardiovascular disease, contribute to neurodegenerative decline, and accelerate biological aging across multiple organ systems. CGM transforms this abstract risk into a visible, actionable data stream.

That is the science. Here is how the Dexcom G7 applies it.

What the Dexcom G7 Does Well

Accuracy is the Dexcom G7’s defining strength. The device has a mean absolute relative difference (MARD) of approximately 8.2%, which places it among the most accurate consumer-grade glucose sensors available. For context, a MARD below 10% is generally considered sufficient for insulin dosing decisions, and the G7 consistently meets this threshold. This level of accuracy means the glucose readings you see on your phone closely reflect what a venous blood draw would show, with the advantage of updating every five minutes rather than once per clinic visit.

The G7’s form factor is a significant advancement over previous generations. The sensor and transmitter are integrated into a single disposable unit that is roughly 60% smaller than the Dexcom G6. Application takes less than a minute using a simple auto-applicator, and most users report that the sensor is comfortable enough to forget they are wearing it. The low profile makes it easy to conceal under clothing, which matters for users who prefer discretion.

Real-time alerts are clinically valuable for diabetic users and informative for wellness-focused users. The G7 can notify you when glucose rises above or drops below customizable thresholds, and “urgent low” alerts provide a critical safety net for insulin-dependent users at risk of hypoglycemia. For nondiabetic users exploring metabolic health, the alert system provides immediate feedback when a meal or activity pushes glucose outside the target range.

Direct-to-watch connectivity is a feature that sets the G7 apart from most competitors. Users can view their current glucose level and trend arrow directly on an Apple Watch or compatible Garmin watch face without pulling out their phone. For athletes and active users, this wrist-level access during workouts, runs, or cycling sessions is a meaningful convenience that supports real-time metabolic decision-making.

Pricing, Access, and Practical Realities

The Dexcom G7 operates on a sensor replacement model. Each sensor lasts 10 days, and a month of continuous monitoring requires three sensors. The cash price without insurance is approximately $350 to $400 per month, making it one of the more expensive consumer health monitoring devices on the market. For individuals with type 1 or type 2 diabetes, insurance coverage often reduces the out-of-pocket cost significantly, sometimes to as little as $0 to $75 per month depending on the plan.

A prescription is required to purchase the Dexcom G7 for diabetic use. However, Dexcom’s over-the-counter variant, the Stelo, is available without a prescription at a lower price point for individuals who do not have diabetes but want to explore continuous glucose monitoring for wellness purposes.

The G7 is HSA and FSA eligible, which allows consumers to use pre-tax healthcare dollars for the purchase. This effectively reduces the real cost by 20% to 35% depending on the user’s tax bracket. The device does not require a separate receiver; any compatible smartphone serves as the display and data hub.

First-year cost of ownership at the cash price is approximately $4,200 to $4,800. This positions the G7 as a premium metabolic health tool, best suited for individuals who are either managing diabetes (with insurance offset) or who have made a deliberate commitment to metabolic optimization and are willing to invest at the level of a monthly gym membership or personal training session.

The FDA clearance for the Dexcom G7 covers use in individuals with type 1 and type 2 diabetes. It is cleared for insulin dosing decisions without a confirmatory fingerstick. For nondiabetic users, the device is used off-label, which is a common practice in the wellness and longevity community but worth acknowledging from a regulatory perspective.

Who the Dexcom G7 Is Best For

The Dexcom G7 is the clear choice for individuals with type 1 or type 2 diabetes who need clinical-grade continuous glucose monitoring with the highest available accuracy and real-time alert capabilities. It is also well suited for athletes and performance-focused individuals who want to understand how nutrition, training, and recovery affect their glucose dynamics at a granular level. The direct-to-watch feature makes it particularly appealing for active users who need wrist-level data during workouts.

Metabolic health enthusiasts and longevity-focused individuals who are willing to invest $350+ per month will find the G7’s accuracy and real-time streaming unmatched. It pairs well with structured nutrition experiments, fasting protocols, and Zone 2 training programs where glucose response is a key performance indicator.

Consumers who may want to look elsewhere include those who are primarily interested in metabolic health curiosity without a clinical need. The Dexcom Stelo offers similar technology at $99 per month without a prescription. Budget-conscious users should also consider the Abbott FreeStyle Libre 3, which provides comparable CGM functionality at a lower price point. Individuals who want a comprehensive software analytics layer with metabolic scoring and food response analysis may prefer platforms like Levels Health or Nutrisense, which bundle CGM sensors with proprietary software and coaching.

How the Dexcom G7 Compares

The Abbott FreeStyle Libre 3 is the Dexcom G7’s most direct competitor. The Libre 3 offers a 14-day sensor (compared to the G7’s 10-day), a slightly smaller sensor profile, and a lower cash price of $75 to $235 per month. Both devices provide real-time glucose streaming, trend arrows, and customizable alerts. The G7 holds an edge in accuracy (MARD of approximately 8.2% versus the Libre 3’s approximately 7.9%, depending on the study) and in smartwatch connectivity. The Libre 3 wins on cost and sensor longevity. For most users, the choice between these two comes down to insurance coverage, form factor preference, and whether direct-to-watch display is a priority.

The Medtronic Guardian 4 occupies a specialized niche. It is designed primarily for integration with Medtronic’s MiniMed 780G insulin pump system, creating a closed-loop automated insulin delivery system. The Guardian 4 uses a 7-day sensor and requires calibration fingersticks, which makes it less convenient as a standalone CGM. It is best suited for type 1 diabetics who are already on or transitioning to Medtronic’s insulin pump ecosystem.

The Dexcom Stelo is Dexcom’s own OTC alternative. It uses a 15-day sensor and costs approximately $99 per month. However, it does not include hypoglycemia alerts and is positioned for wellness monitoring rather than diabetes management. For nondiabetic users exploring CGM for the first time, the Stelo offers a more accessible entry point to Dexcom’s technology at less than a third of the G7’s cost.

Limitations and Open Questions

The Dexcom G7’s most significant limitation for nondiabetic users is cost. At $350 to $400 per month, it represents one of the highest ongoing expenses in the consumer health technology landscape. Unlike devices that require a one-time purchase, CGM costs recur every month for as long as you want to continue monitoring. This creates a meaningful financial commitment that not all users will sustain long-term.

Sensor accuracy, while industry-leading, is not equivalent to a laboratory blood draw. The G7 measures interstitial fluid glucose, which lags behind blood glucose by approximately 5 to 15 minutes. During periods of rapid glucose change (immediately after a high-glycemic meal or during intense exercise), the sensor reading may not perfectly reflect the current blood glucose level. Users should understand this physiological lag when interpreting real-time data.

For nondiabetic users, the G7 is used off-label. While this is common in the wellness community and supported by a growing body of research on CGM for metabolic health, it means insurance coverage is unlikely for non-diabetes indications. The clinical evidence for CGM in nondiabetic populations is still accumulating, and some healthcare providers remain skeptical of its value for individuals without a diagnosis.

Adhesive sensitivity affects a subset of users. The sensor is attached to the skin with an adhesive patch that must remain in place for 10 days. Some users experience skin irritation, redness, or allergic reactions at the application site. Barrier wipes and over-patches can mitigate this, but it is worth noting for individuals with sensitive skin.

What This Means for Your Health

Glucose metabolism sits at the intersection of nearly every dimension of health that Healthcare Discovery‘s longevity framework addresses. Among the Five Pillars of foundational health, nutrition has the most direct and immediate impact on glucose dynamics. Every meal produces a measurable glucose response, and CGM transforms this response from an invisible abstraction into a visible, traceable signal that you can learn to optimize. Sleep is the second pillar with strong glucose connections: poor sleep raises fasting glucose and impairs insulin sensitivity, effects that CGM can quantify night by night. Movement, particularly resistance training and Zone 2 cardiovascular exercise, improves glucose disposal and reduces glycemic variability, benefits that CGM makes visible in real time. Even breathwork and stress management show up in glucose data, as cortisol-driven stress responses can elevate glucose independently of food intake.

Metabolic dysfunction is one of the Four Villains, the chronic disease categories that the broader medical research community identifies as the primary threats to longevity. Insulin resistance and glycemic dysregulation are upstream drivers of cardiovascular disease, contribute to neurodegenerative pathology, and accelerate the cellular aging processes that underlie multiple disease states. By making glucose dynamics visible and actionable, CGM provides a direct line of sight into one of the most modifiable risk factors for chronic disease.

The Dexcom G7 is not a diagnostic tool, and wearing a CGM does not prevent disease. What it provides is information: the kind of real-time, personalized metabolic data that enables individuals to make evidence-based decisions about how they eat, how they exercise, how they sleep, and how they manage stress. For those committed to building a longevity practice grounded in measurement rather than guesswork, the G7 represents one of the most powerful consumer health tools available today.

Frequently Asked Questions

How accurate is the Dexcom G7 compared to a blood glucose meter?

The Dexcom G7 has a mean absolute relative difference (MARD) of approximately 8.2%, which means its readings are typically within 8.2% of a laboratory blood glucose measurement. This is considered highly accurate for a continuous glucose monitor and is sufficient for insulin dosing decisions without a confirmatory fingerstick. A slight lag of 5 to 15 minutes exists because the sensor measures interstitial fluid rather than blood directly.

Do I need a prescription for the Dexcom G7?

Yes, the Dexcom G7 requires a prescription for purchase and use in diabetes management. For individuals who want CGM without a prescription, Dexcom offers the Stelo, an over-the-counter variant designed for general wellness monitoring at approximately $99 per month. The Stelo uses a 15-day sensor but does not include hypoglycemia alerts.

How much does the Dexcom G7 cost per month?

The cash price without insurance is approximately $350 to $400 per month for three 10-day sensors. With insurance coverage for diabetes, out-of-pocket costs may be as low as $0 to $75 per month depending on the plan. The device is HSA and FSA eligible. First-year cost at the cash price is approximately $4,200 to $4,800.

Can nondiabetic people use the Dexcom G7?

The Dexcom G7 is FDA cleared for use by individuals with type 1 and type 2 diabetes. Nondiabetic use is considered off-label, though it is increasingly common among metabolic health enthusiasts, athletes, and longevity-focused individuals. A physician can write a prescription for off-label use. Alternatively, the Dexcom Stelo is available over the counter without a prescription for wellness monitoring.

How long does each Dexcom G7 sensor last?

Each Dexcom G7 sensor lasts 10 days, after which it must be replaced. The sensor includes a 12-hour warm-up period after application during which readings may be less stable. A month of continuous monitoring requires approximately three sensors. Application takes less than a minute using the integrated auto-applicator.

Does the Dexcom G7 work with smartwatches?

Yes. The Dexcom G7 supports direct-to-watch connectivity with the Apple Watch and select Garmin smartwatch models. Users can view their current glucose level and trend arrow directly on the watch face without needing to check their phone. This feature is particularly valuable during exercise, meetings, or any situation where phone access is inconvenient.

What is the difference between the Dexcom G7 and the Dexcom Stelo?

The Dexcom G7 is a prescription CGM cleared for diabetes management, with a 10-day sensor, hypoglycemia alerts, and insulin dosing clearance. The Stelo is an over-the-counter wellness CGM with a 15-day sensor, no hypoglycemia alerts, and a price of approximately $99 per month. The G7 offers higher clinical functionality; the Stelo offers accessibility and lower cost for nondiabetic users exploring metabolic health monitoring.

{“@context”:”https://schema.org”,”@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”How accurate is the Dexcom G7?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The Dexcom G7 has a mean absolute relative difference (MARD) of approximately 8.2%, meaning its readings are typically within 8.2% of a laboratory blood glucose measurement. This is considered highly accurate for a continuous glucose monitor and is sufficient for insulin dosing decisions without a confirmatory fingerstick.”}},{“@type”:”Question”,”name”:”How much does the Dexcom G7 cost per month?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The cash price without insurance is approximately $350 to $400 per month for three 10-day sensors. With insurance coverage for diabetes, out-of-pocket costs may be as low as $0 to $75 per month. The device is HSA and FSA eligible. First-year cost at the cash price is approximately $4,200 to $4,800.”}},{“@type”:”Question”,”name”:”Can nondiabetic people use the Dexcom G7?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The Dexcom G7 is FDA cleared for individuals with type 1 and type 2 diabetes. Nondiabetic use is considered off-label but increasingly common among metabolic health enthusiasts and athletes. A physician can write a prescription for off-label use. Alternatively, the Dexcom Stelo is available over the counter without a prescription for wellness monitoring.”}}]}